Answers are grounded in this paper and cite their sources.
Compared with pioglitazone, ipragliflozin exerts equally beneficial effects on NAFLD and glycemic control during the treatment of patients with type 2 diabetes complicated by NAFLD. Furthermore, ipragliflozin significantly reduced body weight and abdominal fat area.
No takes yet. Share an insight, caveat, or question.
Ito et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: